|
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion For U S Residents Only ENJAYMO Patient Solutions ( 1-833-223-2428 )
- Sutimlimab - Wikipedia
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD) [ 1 ] [ 3 ] [ 4 ] It is given by intravenous infusion [ 1 ] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro
- Enjaymo: Uses, Dosage, Side Effects Warnings - Drugs. com
Enjaymo is a prescription medicine that affects your immune system Enjaymo can lower the ability of your immune system to fight infections People who take Enjaymo may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae, and Haemophilus influenzae
- HIGHLIGHTS OF PRESCRIBING INFORMATION . . . - Sanofi
ENJAYMO intravenously weekly for the first two weeks, with administration every two weeks thereafter Administer ENJAYMO at the recommended dosage regimen time points, or within two days of these time points If a dose is missed, administer as soon as possible; thereafter, resume dosing every two weeks
- ENJAYMO® (sutimlimab-jome) | Healthcare Professional Website
ENJAYMO, a proximal classical complement C1s inhibitor, increases susceptibility to serious infections, including those caused by encapsulated bacteria e g Neisseria meningitidis (any serogroup, including non-groupable strains), Streptococcus pneumoniae, and Haemophilus influenzae type B
- Enjaymo | European Medicines Agency (EMA)
Enjaymo is a medicine for treating haemolytic anaemia (excess breakdown of red blood cells) in adults with cold agglutinin disease (CAD) CAD is a rare blood disorder where the immune system (the body’s natural defence) recognises red blood cells as foreign and attacks them
- FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE
ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD) 2 DOSAGE AND ADMINISTRATION 2 1 Recommended Vaccinations Vaccinate patients against encapsulated bacteria at least 2 weeks prior to initiation of ENJAYMO therapy according to the most current Advisory Committee on Immunization
- FDA Approves Enjaymo® after pivotal study results | Sanofi
Enjaymo is the only approved treatment to inhibit red blood cell destruction in CAD and help stop the chain reaction from the start ” CAD, a rare autoimmune hemolytic anemia, is caused by antibodies called cold agglutinins binding to the surface of red blood cells, which starts a process that causes the body’s immune system to mistakenly
|
|
|